High Cholesterol

About High Cholesterol Clinical Trials (Click to Open)

Join Clinical Trials for High Cholesterol

clinical trials for high cholesterolGeneral Purpose:

Though high cholesterol on its own may not have symptoms, those with it are more prone to developing coronary heart disease. Lowering your cholesterol is a critical step in preventing heart disease and blood clots. This condition is treated with medications and behavioral changes, such as diet and exercise.

The aim of clinical research is to find new and improved treatments, generally to lower your low-density lipoprotein (LDL) cholesterol level, as it is increased LDL levels that increase your risk for developing heart disease, having a heart attack, and other serious health threats.

Certain trials are attempting to expand the scientific knowledge of these lipoproteins, to better understand the factors that affect these levels. In observational studies as this, you may not personally benefit by participating, but you will help researchers develop improved diagnostic and treatment measures for individuals with high cholesterol.

Moreover, given that high cholesterol is often associated with other diseases, many clinical trials will be monitoring cholesterol levels in relation to such diseases as heart disease and diabetes. Though some studies will specifically be looking at dyslipidemia (high blood cholesterol levels), in order to assess improved medications or behavioral programs.

What will High Cholesterol Clinical Trials be like?

Before joining a clinical trial, researchers will first assess your eligibility. You will go through a screening phase to ensure that you are an appropriate participant for the aims of the trial. Since there are many crossover trials with other diseases, you may gain the most benefit by joining a study that involves another condition that you also have.

Moreover, if a trial is looking at a potential relationship between a vitamin deficiency and high cholesterol, they will likely only include individuals with both conditions. The goal of these trials is to lower cholesterol and prevent individuals with high cholesterol from developing more serious conditions, so inclusion criteria is put in place to facilitate this benefit and avoid wasting your time.

They are also put in place to avoid any risk of a detrimental interaction between a behavioral or pharmaceutical intervention and an existing condition or medication. The researchers will therefore ask you to provide a very detailed medical history.

Typical High Cholesterol Clinical Trial Protocol:

If the main interventional method being tested is a new pharmaceutical, you will be clinical trials for high cholesterolrandomly assigned to a group that either receives a varying dose of the treatment or a placebo. To evaluate this intervention, participants may be asked to visit for follow up examinations and/or take follow up questionnaires.

Lifestyle plays a contributive role on cholesterol levels; many trials intend to uncover the most beneficial behavioral changes for individuals with high cholesterol. Participants will undergo relevant baseline assessments, and continuous monitoring throughout the trial.

These trials will attempt to provide you personal benefit to reduce your cholesterol levels and risk of heart disease, as well benefit others struggling with high cholesterol.

Suggested Search Terms:

Lowering Cholesterol Levels, Dyslipidemia, High Cholesterol and Hypertension, Reducing the Risk of Heart Disease, Evaluation of Lipoproteins 

Current Search Term:

High Cholesterol

Add Comments or Questions



A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe 10 mg;   Drug: Rosuvastatin 2.5 mg;   Drug: Placebo for Ezetimibe;   Drug: Placebo for Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified January 2017


Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Lactoflorene colesterolo;   Dietary Supplement: Placebo lactoflorene colesterolo
Sponsor:   Montefarmaco OTC SpA
Active, not recruiting - verified February 2017


A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins


Condition:   Hypercholesteremia
Interventions:   Drug: Gemcabene 600 mg;   Drug: Placebo
Sponsor:   Gemphire Therapeutics, Inc.
Recruiting - verified November 2016


A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: CAT-2054;   Drug: Placebo;   Drug: Atorvastatin
Sponsor:   Catabasis Pharmaceuticals
Completed - verified July 2016


A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe 10 mg;   Drug: Atorvastatin 10 mg;   Drug: Placebo for Ezetimibe 10 mg tablet;   Drug: Placebo for Atorvastatin 10 mg capsule;   Behavioral: Diet control/Daily Exercise
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified June 2016


A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Terminated - verified August 2016


A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: Evacetrapib;   Drug: Ezetimibe;   Drug: Atorvastatin;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Terminated - verified August 2016


Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)


Condition:   Hypercholesterolemia
Interventions:   Drug: Alirocumab;   Drug: Placebo (for Alirocumab);   Drug: Non-statin LMT;   Other: Diet Alone
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified January 2017


A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository


Condition:   Homozygous Familial Hypercholesterolemia
Intervention:  
Sponsor:   The Rogosin Institute
Recruiting - verified March 2017


Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)


Condition:   Primary Hypercholesterolemia
Interventions:   Drug: ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients


Condition:   Familial Hypercholesterolemia
Interventions:   Drug: APL180;   Drug: APL180;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Withdrawn - verified September 2016


Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)


Condition:   Hypercholesterolemia
Interventions:   Drug: Atorvastatin 10 mg;   Drug: Ezetimibe 10 mg/simvastatin 20 mg;   Drug: Atorvastatin 20 mg;   Drug: Ezetimibe 10 mg/simvastatin 40 mg;   Drug: Atorvastatin 40 mg
Sponsors:   Merck Sharp & Dohme Corp.;   Merck Shering-Plough JV Study
Completed - verified March 2017


Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: Lapaquistat acetate and stable statin therapy;   Drug: Stable statin therapy
Sponsor:   Takeda
Terminated - verified June 2016


A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: Comparator : rosuvastatin calcium;   Drug: Comparator: Placebo (unspecified);   Drug: Comparator: Placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)


Condition:   Hypercholesterolemia
Intervention:   Drug: MK0733, simvastatin / Duration of Treatment: 12 Weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: ezetimibe;   Drug: Comparator: placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653A, ezetimibe (+) simvastatin;   Drug: Comparators: simvastatin and ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)


Condition:   Hypercholesterolemia
Intervention:   Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653A, ezetimibe (+) simvastatin;   Drug: Comparator: atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653, ezetimibe;   Drug: Comparator: statins
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017


Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0733, simvastatin;   Drug: Comparator: simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers


Conditions:   Atherosclerosis;   Hypercholesterolemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 22, 2017

Refine Your Search Advanced Search